Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices
FDA and Off-Label Communications: What Happens Now?
The drugmaker's lead product, Rasuvo, is an injectable version of a commonly prescribed drug used to treat rheumatoid arthritis.
Opdivo's new melanoma indication denied; Novartis weighs sale of contact lens portfolio; Sanofi prepares to sell Merial
The agency launched a giving campaign to celebrate the life of Christophe Foultier.
FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan
The contract sales organization plans to sell its commercial services business to Publicis Healthcare Communications Group.